Table 3.
Distribution, involvement of levels, and pre- and postoperative visual analogue scales with preoperative symptom duration and follow-up duration of each patient in the steroid group
| No | Sex | Age (years) | Level | Duration (weeks) | SLR | Pre-op VAS | PO 2W VAS | PO 1M VAS | PO 3M VAS | PO 6M VAS | PO 1Y VAS | Final VAS | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 24 | L4-5 | 2 | + | 7.9 | 2.6 | 2.1 | 2.3 | 2.7 | 3.3 | 3.4 | 28 |
| 2 | M | 25 | L4-5 | 5 | + | 7.7 | 3.1 | 2.5 | 2.6 | 2.8 | 3.2 | 3.1 | 31 |
| 3 | M | 44 | L4-5 | 7 | + | 8.2 | 3.2 | 2.6 | 2.8 | 2.7 | 3.4 | 3.6 | 34 |
| 4 | M | 19 | L4-5 | 8 | + | 8.3 | 2.9 | 2.7 | 2.7 | 2.6 | 3.3 | 3.5 | 35 |
| 5 | M | 43 | L4-5 | 9 | + | 8.5 | 3.1 | 2.6 | 2.8 | 2.9 | 3.2 | 3.6 | 29 |
| 6 | M | 34 | L4-5 | 5 | + | 8.6 | 3.3 | 2.5 | 2.9 | 2.9 | 3.1 | 3.4 | 33 |
| 7 | F | 33 | L4-5 | 4 | + | 7.6 | 3.2 | 2.7 | 3 | 3.1 | 3.4 | 3.7 | 28 |
| 8 | M | 32 | L4-5 | 2 | + | 6.9 | 2.9 | 2.4 | 2.6 | 2.7 | 3.1 | 3.6 | 29 |
| 9 | M | 20 | L4-5 | 3 | + | 7.6 | 2.8 | 2.3 | 2.7 | 2.8 | 3.2 | 3.6 | 34 |
| 10 | M | 36 | L5-S1 | 6 | + | 7.5 | 3.1 | 2.6 | 2.9 | 3.1 | 3.3 | 3.5 | 35 |
| 11 | M | 20 | L4-5 | 5 | + | 7.8 | 3.4 | 2.9 | 3 | 3.2 | 3.4 | 3.7 | 31 |
| 12 | M | 24 | L4-5 | 7 | + | 7.7 | 3.6 | 2.7 | 2.9 | 3.2 | 3.5 | 3.6 | 30 |
| 13 | M | 26 | L5-S1 | 6 | + | 7.6 | 3.2 | 2.8 | 2.9 | 3.4 | 3.4 | 3.4 | 29 |
| 14 | F | 26 | L5-S1 | 10 | + | 8.1 | 3.3 | 2.5 | 2.9 | 3.1 | 3.2 | 3.6 | 28 |
| 15 | F | 28 | L4-5 | 6 | + | 7.8 | 3.4 | 2.6 | 3.3 | 3.5 | 3.3 | 3.1 | 27 |
| 16 | M | 37 | L4-5 | 4 | + | 7.5 | 3.1 | 2.7 | 3.2 | 3.3 | 3.4 | 3.1 | 33 |
| 17 | F | 25 | L4-5 | 3 | + | 8.2 | 3.2 | 2.8 | 3.1 | 3.2 | 3.3 | 3.2 | 25 |
| 18 | M | 32 | L4-5 | 4 | + | 8.1 | 2.5 | 2.4 | 3.6 | 3.4 | 3.6 | 3.3 | 28 |
| 19 | M | 33 | L5-S1 | 2 | + | 8.2 | 1.9 | 2.4 | 3.2 | 3.1 | 3.1 | 3.4 | 29 |
| 20 | M | 34 | L4-5 | 3 | + | 7.8 | 2.4 | 2.6 | 3.3 | 3.6 | 3.5 | 3.3 | 34 |
| 21 | M | 27 | L5-S1 | 8 | + | 7.6 | 2.7 | 2.4 | 3.5 | 3.4 | 3.6 | 3.4 | 33 |
| 22 | M | 40 | L4-5 | 6 | + | 7.6 | 2.5 | 2.3 | 2.7 | 3.4 | 3.4 | 3.1 | 39 |
| 23 | M | 22 | L5-S1 | 7 | + | 7.9 | 3.3 | 3 | 2.9 | 3.3 | 3.7 | 37 | |
| 24 | F | 41 | L5-S1 | 10 | + | 7.6 | 3.1 | 2.7 | 2.9 | 3.6 | 3.4 | 3.5 | 33 |
| 25 | M | 38 | L4-5 | 11 | + | 7.8 | 3.2 | 2.6 | 3.1 | 3.3 | 3.6 | 3.6 | 32 |
| 26 | M | 25 | L4-5 | 9 | + | 8.1 | 3.2 | 2.4 | 2.6 | 3.2 | 3.5 | 34 | 31 |
| 27 | M | 26 | L4-5 | 8 | + | 7.6 | 2.6 | 2.3 | 2.7 | 3.2 | 3.4 | 3.2 | 31 |
| 28 | M | 28 | L5-S1 | 5 | + | 7.8 | 2.7 | 2.5 | 2.6 | 3.1 | 3.6 | 3.1 | 30 |
| 29 | M | 23 | L4-5 | 6 | + | 7.5 | 2.4 | 2.2 | 2.5 | 2.8 | 3.4 | 3.3 | 29 |
SLR straight leg raising test, Duration duration of symptoms in weeks before operation, Pre-op VAS preoperative visual analogue scale, PO 2W VAS postoperative visual analogue scale at 2 weeks, PO 1M VAS postoperative visual analogue scale at 1 month, PO 3M VAS postoperative visual analogue scale at 3 months, PO 6M VAS postoperative visual analogue scale at 6 months, PO 1Y VAS postoperative visual analogue scale at 1 year